


Next-Gen Immunotherapies Market to Grow at 7.2% CAGR, During 2024-2031 | DataM Intelligence

The next-gen immunotherapies market is evolving with biotech advances, rising cancer cases, new therapies, funding, and global innovation driving growth.

NEW YORK, NY, UNITED STATES, May 27, 2025 /EINPresswire.com/ -- Market Overview

The [Next-generation immunotherapies market](#) is undergoing a significant transformation as biotech innovations redefine how we fight complex diseases such as cancer, autoimmune disorders, and infectious diseases. Driven by personalized therapies, advanced cell engineering, and supportive regulatory pathways, the market is projected to grow at a CAGR of 7.2% in the coming years.



Market Drivers

“

Next-gen immunotherapies go beyond treatment they represent the cutting edge of precision medicine in real-world application.”

DataM Intelligence

Increasing global cancer prevalence is creating a strong demand for innovative treatment approaches

Significant progress in CAR-T and TCR-T cell technologies is reshaping the therapeutic landscape
Accelerated innovation in mRNA platforms and gene-editing tools is enhancing immunotherapy potential

Public sector investments and financial incentives are

fueling immunotherapy research and trials

Strategic partnerships between biotech companies and research institutions are driving pipeline

growth

Regulatory agencies are granting more approvals for advanced biologics and cell-based therapies

Get Premium Sample Report Pdf: <https://www.datamintelligence.com/download-sample/next-generation-immunotherapies-market>

Market Segmentation

By Immunotherapy Type - Monoclonal Antibodies, Immune Checkpoint Inhibitors, Non-specific Immunotherapies (Cytokines, Bacillus Calmette-Guerin (BCG)), Antibody Drug Conjugate, Cellular Therapy (T-Cell Therapy, B-Cell Therapy), Others

By Route of Administration - Oral, Parenteral

By Distribution Channel - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Latest News of USA

The United States is leading the way in next-generation immunotherapy innovation. In early 2025, the FDA approved a groundbreaking CAR-T cell therapy developed by Gilead Sciences for the treatment of relapsed lymphoma, marking a pivotal moment in personalized cancer care. Meanwhile, Moderna announced a strategic partnership with Merck to co-develop a new mRNA-based cancer vaccine, now moving into phase II trials. Additionally, NIH launched a \$150 million funding initiative to support early-stage biotech firms exploring TCR-T therapies and oncolytic virus platforms.

Latest News of Japan

Japan is rapidly advancing its role in the global immunotherapy market through both policy and innovation. In 2025, the Japanese government approved new reimbursement guidelines for CAR-T treatments, making them more accessible to cancer patients. Furthermore, Osaka University initiated Asia's first clinical trial for a CRISPR-based TCR-T therapy targeting pancreatic cancer. Japanese pharmaceutical giant Takeda is investing over \$200 million to expand its immunotherapy R&D unit, with a focus on autoimmune conditions and novel checkpoint inhibitors.

Market Key Players

A number of prominent players are driving innovation and commercialization within the space. These include:

AstraZeneca
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
MacroGenics, Inc.
Mereo Biopharma Group PLC
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sorrento Therapeutics

Many of these companies are actively engaged in mergers, licensing deals, and late-stage clinical trials to expand their therapeutic pipelines.

Key Developments:

Sept 11, 2023: Pfizer and BioNTech received FDA clearance for their Omicron XBB.1.5-adapted COVID-19 vaccine for ages 6 months and up.

Jan 9, 2023: 3T Biosciences and Boehringer Ingelheim partnered to co-develop advanced cancer therapies using the 3T-TRACE platform.

Conclusion

The next-generation immunotherapies market is on the brink of a revolutionary shift over the coming decade. As scientific breakthroughs align with regulatory support and increasing global healthcare needs, companies and countries are investing heavily to bring safer, more effective, and personalized treatments to patients. With strong market push in regions like the U.S. and Japan, the field is evolving beyond oncology into a wider spectrum of diseases marking a revolutionary shift in how medicine will be delivered in the future.

Related Reports

[Immuno Oncology Assays Market Analysis 2025 - 2033](#)

[Antibody Drug Conjugates Market Size 2024 - 2031](#)

Sai Kumar
DataM Intelligence 4market Research LLP
+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/816415738>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.